Ray Manneh Kopp
A5057427171- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- COVID-19 and healthcare impacts
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Renal and related cancers
- Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- Neuroblastoma Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Advanced Breast Cancer Therapies
Popular University of Cesar
2020-2025
University College London
2024
Dana-Farber Cancer Institute
2024
The Royal Free Hospital
2024
Beatson West of Scotland Cancer Centre
2024
Queen Mary University of London
2024
University of Glasgow
2024
Université Paris-Saclay
2024
Palacký University Olomouc
2024
Asociación Colombiana de Gastroenterología
2023
BackgroundBelzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma early-phase studies.MethodsIn phase 3, multicenter, open-label, active-controlled trial, we enrolled participants with advanced who had previously received immune checkpoint and antiangiogenic therapies randomly assigned them, 1:1 ratio, to receive 120 mg of belzutifan or 10 everolimus orally once daily until disease progression unacceptable toxic effects occurred. The...
The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. randomized, double-blind, phase III KEYNOTE-921 trial (Clinicaltrials.gov identifier: NCT03834506) evaluated the efficacy and safety pembrolizumab or placebo plus docetaxel previously treated mCRPC. Adults with mCRPC who progressed androgen-deprivation one ARPI were randomly assigned 1:1 to concomitant prednisone. Dual...
Abstract Background Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Patients and Methods Medical records with documented metastatic UC treated by as second-line therapy were retrospectively collected from 88 institutions 23 countries. assessed for overall survival (OS),...
About 20% of patients with renal cell carcinoma present non-clear histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role cytoreductive nephrectomy (CN) in metastatic nccRCC is contentious. Limited data exist on CN under current standard care. This retrospective study focused impact upfront outcomes first-line immune checkpoint inhibitor (IO) combinations or tyrosine kinase (TKI) monotherapy. The included 221 and...
508 Background: Hypoxia-inducible factor 2⍺ (HIF) inhibitors are active in renal cell carcinoma refractory to prior treatment with tyrosine kinase (TKI) and immunotherapy, including anti-PD-1 monotherapy or combinations anti-CTLA-4, represent a new therapeutic option. However, the efficacy of TT after HIF-2⍺ has not been assessed. Methods: A retrospective review medical records from aRCC patients (pts) treated HIF-2a at five academic institutions was conducted. Pts who received subsequent...
502 Background: Deferred cytoreductive nephrectomy (dCN) is an emerging, strategy in the management of metastatic renal cell carcinoma (mRCC), applied selectively to patients who demonstrate a favorable response initial systemic therapy. This study aimed assess clinical impact dCN within context sequential treatment management. Methods: A multi-institutional retrospective evaluation. The descriptive analysis was performed examine demographic and characteristics. Progression-free survival...
The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction immune-based combinations. role cytoreductive nephrectomy (CN) in these patients is still debated. ARON-1 study (NCT05287464) was designed to globally analyze real-world data mRCC receiving first-line immuno-oncology This sub-analysis focused on or delayed partial radical CN three geographical areas (Western Europe, Eastern America/Asia).We conducted a multicenter retrospective...
Abstract Background There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and on first-line combinations are lacking. Method This was a real-world, multicenter, international, observational study determine the effects clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated immuno-oncology therapy. Results A total of 1827 mRCC from 71 cancer centers 21...
Urothelial cancer accounts for approximately 3% of new cases worldwide, with a high burden disease in countries medium and low human development indexes where its incidence mortality are increasing. The purpose this consensus is to develop statements on the evaluation treatment locally advanced metastatic urothelial carcinoma that would further guide clinical practice Latin America.
Introduction and objective: The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over time the advent of new therapies multimodal strategies. objective this consensus experts is generate national recommendations for profiling management OEC, defined as stages III IV “The International Federation Gynecology Obstetrics (FIGO) classification at diagnosis base on literature review that included international evidence-based clinical practice...
In Colombia and worldwide, breast cancer (BC) is the most frequently diagnosed neoplasia leading cause of death from among women. Studies predominantly involve hereditary familial cases, demonstrating a gap in literature regarding identification germline mutations unselected patients Latin-America. Identification pathogenic/likely pathogenic (P/LP) variants important for shaping national genetic analysis policies, counseling, early detection strategies. The present study included 400 women...
Traditionally, bladder cancer has been classified based on histology features. Recently, some works have proposed a molecular classification of invasive tumors. To determine whether proteomics can define subtypes muscle urothelial (MIUC) and allow evaluating the status biological processes its clinical value. 58 MIUC patients who underwent curative surgical resection at our institution between 2006 2012 were included. Proteome was evaluated by high-throughput in routinely archive FFPE tumor...
The prevalence of homologous recombination repair gene mutations (HRRm) in patients with metastatic castration-resistant prostate cancer (mCRPC) Latin America and the Caribbean (LAC) is unknown. Prevalence Recombination (HRR) mutatiOns patientS castration resistant ProstatE Cancer LaTin (PROSPECT) aimed to determine this describe demographic clinical characteristics participants.